Correspondence 0001185185-24-000033 from IGC Pharma, Inc. (IGC)

IGC Pharma, Inc.
Date: Jan. 4, 2024 · CIK: 0001326205 · Accession: 0001185185-24-000033

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-276330

Date

January 4, 2024

Author

Kenneth Schlesinger

Form

CORRESP

Company

IGC Pharma, Inc.

Letter

igcpharma20240104_corresp.htm

January 4, 2024

VIA EMAIL AND EDGAR

U.S. Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Attention: Jessica Dickerson, Esq.

Division of Corporation Finance

Re: IGC Pharma, Inc.

Registration Statement on Form S-3 (No. 333-276330)

Ladies and Gentlemen:

On behalf of IGC Pharma, Inc. (the “Company”), we enclose the Company’s request for acceleration of the above-referenced Registration Statement to 4:00 p.m., Eastern time, on Monday, January 8, 2024, or as soon as possible thereafter.

Please advise the undersigned of the effectiveness of the Registration Statement.

Very truly yours,

/s/ Kenneth Schlesinger

Kenneth Schlesinger

cc: Mr. Ram Mukunda

Ms. Claudia Grimaldi

IGC Pharma, Inc.

10224 Falls Road

Potomac, MD 20854

January 4, 2024

U.S. Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Attention: Jessica Dickerson, Esq.

Division of Corporation Finance

Re: IGC Pharma, Inc.

Registration Statement on Form S-3 (No. 333-276330)

Ladies and Gentlemen:

IGC Pharma, Inc. hereby requests that the effectiveness of the above-referenced Registration Statement be accelerated so that it will become effective at 4:00 p.m., Eastern time, on Monday, January 8, 2024, or as soon as possible thereafter.

Very truly yours,
IGC PHARMA, INC.

Show Raw Text

CORRESP
1
filename1.htm

	igcpharma20240104_corresp.htm

January 4, 2024

VIA EMAIL AND EDGAR

U.S. Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Attention:         Jessica Dickerson, Esq.

                         Division of Corporation Finance

Re:         IGC Pharma, Inc.

Registration Statement on Form S-3 (No. 333-276330)

Ladies and Gentlemen:

On behalf of IGC Pharma, Inc. (the “Company”), we enclose the Company’s request for acceleration of the above-referenced Registration Statement to 4:00 p.m., Eastern time, on Monday, January 8, 2024, or as soon as possible thereafter.

Please advise the undersigned of the effectiveness of the Registration Statement.

			Very truly yours,

			/s/ Kenneth Schlesinger

			Kenneth Schlesinger

cc:          Mr. Ram Mukunda

Ms. Claudia Grimaldi

IGC Pharma, Inc.

10224 Falls Road

Potomac, MD 20854

January 4, 2024

U.S. Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Attention:         Jessica Dickerson, Esq.

                         Division of Corporation Finance

Re:         IGC Pharma, Inc.

Registration Statement on Form S-3 (No. 333-276330)

Ladies and Gentlemen:

IGC Pharma, Inc. hereby requests that the effectiveness of the above-referenced Registration Statement be accelerated so that it will become effective at 4:00 p.m., Eastern time, on Monday, January 8, 2024, or as soon as possible thereafter.

			Very truly yours,

			IGC PHARMA, INC.

			By:

			/s/ Ram Mukunda

			Ram Mukunda

			Chief Executive Officer and President

SecProbe.io